Daniel Rayson

5.2k total citations
137 papers, 3.4k citations indexed

About

Daniel Rayson is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniel Rayson has authored 137 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 33 papers in Cancer Research and 27 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel Rayson's work include HER2/EGFR in Cancer Research (32 papers), Breast Cancer Treatment Studies (31 papers) and Cancer Treatment and Pharmacology (24 papers). Daniel Rayson is often cited by papers focused on HER2/EGFR in Cancer Research (32 papers), Breast Cancer Treatment Studies (31 papers) and Cancer Treatment and Pharmacology (24 papers). Daniel Rayson collaborates with scholars based in Canada, United States and United Kingdom. Daniel Rayson's co-authors include Tallal Younis, Chris Skedgel, Penny J. Barnes, Stephen Chia, T. Younis, Lester E. Wold, Vera J. Suman, Karen A. Gelmon, Susan Dent and Alex A. Adjei and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Daniel Rayson

131 papers receiving 3.3k citations

Peers

Countries citing papers authored by Daniel Rayson

Since Specialization

Citations

This map shows the geographic impact of Daniel Rayson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Rayson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Rayson more than expected).

Fields of papers citing papers by Daniel Rayson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Rayson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Rayson. The network helps show where Daniel Rayson may publish in the future.

Co-authorship network of co-authors of Daniel Rayson

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Rayson. A scholar is included among the top collaborators of Daniel Rayson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Rayson. Daniel Rayson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective 2023 ·Current Oncology ·Jan‐Willem Henning, Christine Brezden‐Masley, Karen A. Gelmon, Stephen Chia, Shane Shapera, Micheal McInnis, Daniel Rayson, Jamil Asselah	17
2	Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain 2022 ·Current Oncology ·Daniel Rayson, Sonal Gandhi, Anil A. Joy, Christine Brezden‐Masley, Karen A. Gelmon, Sandeep Sehdev, David W. Cescon, Stephen Chia	2
3	Complete response of a colonic high-grade neuroendocrine carcinoma to platinum-based therapy: Insights from comprehensive genomic profiling 2021 ·American Journal of Clinical Pathology ·(unknown), Thomas Arnason, (unknown), Daniel Gaston, (unknown), Daniel Rayson	2
4	Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid 2016 ·Clinical Colorectal Cancer ·Michael Yan, Cheryl Ho, Eric Winquist, Derek J. Jonker, Daniel Rayson, Larry Stitt, Sonya Tokmakejian, Anna Tomiak, Mark Vincent	7
5	Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review 2016 ·Breast Cancer Research and Treatment ·T. Younis, Daniel Rayson, Snežana Jovanović, Chris Skedgel	14
6	Cost–Utility of Adjuvant Zoledronic Acid in Patients with Breast Cancer and Low Estrogen Levels 2015 ·Current Oncology ·(unknown), Chris Skedgel, Daniel Rayson, T. Younis	0
7	Terry Fox: Canadian Cancer Research Activist Whose “Marathon of Hope” Inspired Millions 2014 ·Mayo Clinic Proceedings ·David P. Steensma, Daniel Rayson, Marc A. Shampo, Robert A. Kyle	3
8	Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer? 2013 ·Annals of Oncology ·Chris Skedgel, Daniel Rayson, T. Younis	10
9	HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer 2013 ·The Oncologist ·Sunil Verma, Anil A. Joy, Daniel Rayson, Deanna McLeod, Christine Brezden‐Masley, Jean-François Boileau, Karen A. Gelmon	11
10	Endocrine Therapy for Postmenopausal Women with Hormone Receptor–Positive her2–Negative Advanced Breast Cancer after Progression or Recurrence on Nonsteroidal Aromatase Inhibitor Therapy: A Canadian Consensus Statement 2013 ·Current Oncology ·Kathleen I. Pritchard, Karen A. Gelmon, Daniel Rayson, Louise Provencher, (unknown), Donald S.A. McLeod, Sunil Verma	19
11	Routine Cardiac Evaluation in Patients With Early-Stage Breast Cancer Before Adjuvant Chemotherapy 2011 ·Clinical Breast Cancer ·(unknown), (unknown), Stephanie Snow, Daniel Rayson, Kara Thompson, Chris Theriault, Tallal Younis	17
12	Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial 2011 ·Annals of Oncology ·Daniel Rayson, Thomas Suter, Christian Jackisch, S. van der Vegt, Begoña Bermejo, Jackie Bosch, Guillermo López-Vivanco, (unknown), Hans Wildiers, A. Antón Torres, Louise Provencher, (unknown), Jacquie Chirgwin, Jean Luc Canon, Gabriella Ferrandina, S. Srinivasan, (unknown), D. J. Richel	33
13	Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality 2010 ·Current Oncology ·(unknown), (unknown), Sayeh Lavasani, John R. Mackey, Kathleen I. Pritchard, Mark Clemons, Susan Dent, Jean Latreille, Julie Lemieux, Louise Provencher, (unknown), (unknown), Stephen Chia, Bo Wang, Daniel Rayson	23
14	Survivin and COX-2 expression in male breast carcinoma 2009 ·The Breast ·Tallal Younis, (unknown), Daniel Rayson, Ron Dewar, Samantha Gray, Penny J. Barnes	11
15	Management of Skin Rash during egfr-Targeted Monoclonal Antibody Treatment for Gastrointestinal Malignancies: Canadian Recommendations 2009 ·Current Oncology ·Barbara Melosky, Ronald L. Burkes, Daniel Rayson, Thierry Alcindor, Neil H. Shear, Mario E. Lacouture	104
16	Anthracycline–trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies 2008 ·Annals of Oncology ·Daniel Rayson, D. J. Richel, Stephen Chia, Christian Jackisch, S. van der Vegt, Thomas Suter	73
17	Waiting Times in Early-Stage Non-small Cell Lung Cancer (NSCLC) 2008 ·Journal of Thoracic Oncology ·Nathalie Saint‐Jacques, Daniel Rayson, Turki Alfayea, Kiran Virik, (unknown), Tallal Younis	32
18	Scleromyxedema: A Complete Response to Prednisone 1999 ·Mayo Clinic Proceedings ·Daniel Rayson, John A. Lust, Alan J. Duncan, (unknown)	18
19	Molecular markers in male breast carcinoma 1998 ·Cancer ·Daniel Rayson, Charles Erlichman, Vera J. Suman, Patrick C. Roche, Lester E. Wold, James N. Ingle, John H. Donohue	113
20	Sarcoidosis and testicular carcinoma 1998 ·Cancer ·Daniel Rayson, Patrick A. Burch, Ronald L. Richardson	73

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact